earticle

영어

Since 2001, ISU ABXIS is a biotech company specialized in developing and manufacturing biological therapeutics, esp., monoclonal antibodies. ISU ABXIS’ strategy is to position itself in the fast growing market of therapeutic antibodies, designed to address the unmet needs of currently marketed therapeutics realizing our fundemental goal of contributing to the development of more effective medicines and improvement of the quality of the life. The ISU ABXIS pipeline is well-focused in biological therapeutics. Based on world-class R&D expertise and GMP facility designed exclusively for mammalian cell production, the 1st biosimilar of antibody therapeutics (Clotinab® vs. ReoPro®) has been successfully launched in worldwide markets. Novel therapeutics has also been developed with best-in-class quality in the areas of cancer and inflammatory diseases. ISU ABXIS has KOL-networked, strong marketing power in domestic markets and manufacturing structure capable of sustaining a worldwide supply. The success record of marketing Clotinab® all around the world underlies in the companies’ capabilities in successful commercialization of R&D products with the best quality.